● 著作（或研究發表）

○ 期刊論文

1. Juang, V., Chang, C.H., Wang, C.S., Chen, Y.C., Wang, H.E., Lo, Y.L.* pH-responsive PEG-shedding and targeting peptide-modified nanoparticles for dual-delivery of irinotecan and microRNA to enhance tumor-specific therapy. Small: in press (SCI; IF = 10.856; Rank = 6.8% in Materials Science, Multidisciplinary).

2. Hong, S.T., Lin, Huaching, Wang, C.S., Chang, C.H., Lin, A.M.Y., Yang, C.H.J., Lo, Y.L.*(2019) Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides. Journal of NanobiotechnologyAug 19;17(1):89 (SCI; IF = 5.345; Rank = 11% in Biotechnology & Applied Microbiology).

3. Chen, Y.J., Hsu, C.C., Shiao, Y.J., Wang, H.T.,Lo, Y.L.*, Lin, A.M.Y.*(2019) Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation. Scientific Reports9(1):2516 (SCI; IF = 4.011; Rank = 21.74% in Multidisciplinary Sciences).

4. Yang, C.P., Shiau,M.Y.,Lai, Y.R., Ho, K.T.,Hsiao, C.W., Chen, C.J., Lo, Y.L., Chang, Y.H.* (2018) Interleukin-4 boosts insulin-induced energy deposits by enhancing glucose uptake and lipogenesis in hepatocytes. Oxid Med Cell Longev. (Oxidative Medicine and Cellular Longevity)6923187 (SCI; IF = 4.868; Rank = 29.02% in Cell Biology).

5. Zhao, W.Z., Wang, H.T., Huang, H.J., Lo, Y.L.*, Lin, A.M.Y.* (2018) Neuroprotective effects of baicalein on acrolein-induced neurotoxicity in the nigrostriatal dopaminergic system of rat brain. Molecular Neurobiology 55(1): 130 (SCI; IF = 4.586; Rank = 21.35% in Neurosciences).

6. Lin, G.L., Ting, H.J., Tseng, T.C.,Juang, V.,Lo, Y.L.*(2017) Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells PLoS One 12(10): e0185625 (SCI; IF = 2.78; Rank = 34.78% in Multidisciplinary Sciences; MOST 104-2320-B-010-004-MY2; MOST 106-2320-B-010-005).

7. Wang, H.T.*, Lin, J.H., Yang, C.H, Haung, C.H., Weng, C.W., Lin, A.M.Y., Lo, Y.L., Chen, W.S., Tang, M.S.(2017)Acrolein induces mtDNA damages, mitochondrial fission and mitophagy in human lung cells.Oncotarget8:70406 (SCI; IF = 5.168; Rank = 20.28% in Oncology).

8. Wang, Y.T., Lin, H.C., Zhao, W.Z., Huang, H.J.,Lo, Y.L., Wang, H.T.*, Lin, A.M.Y.* (2017) Acrolein acts as a neurotoxin in the nigrostriatal dopaminergic system of rat:involvement of α-synuclein aggregation and programmed cell death. Scientific Reports7:45741-45749 (SCI; IF = 4.011; Rank = 21.74% in Multidisciplinary Sciences; MOST 104-2320-B-010-016).

9. Lin, K.H., Hong, S.T., Wang, H.T., Lo, Y.L.*, Lin, A.M.Y.*, Yang, C.H.J. (2016) Enhancing anticancer effect of gefitinib across the blood-brain barrier model using liposomes modified with one alpha-helical cell-penetrating peptide or glutathione and Tween 80.Int. J. Mol. Sci.17 (12):1998-2014(SCI; IF = 4.183; Rank = 26.74% in Biochemistry & Molecular Biology; MOST 104-2320-B-010-004-MY2; VGHUST105-G7-8-3; V105C-031).

10. Juang, V.,Lee, H.P., Lin, A.M.Y.,Lo, Y.L.*(2016) Cationic PEGylated liposomes incorporating an antimicrobial peptide hepcidin 2-3: an adjuvant of epirubicin to overcome multidrug resistance in cervical cancer cells. Int. J. Nanomedicine 11:6047–6064(SCI; IF = 4.47; Rank = 12.73% in Pharmacology & Pharmacy; MOST 104-2320-B-010-004-MY2; VGHUST105-G7-8-3).

11. Lo, Y.L.*,Lee, H.P., Tu, W.C.(2015) The use of a liposomal formulation incorporating an antimicrobial peptide from tilapia as a new adjuvant to epirubicin in human squamous cell carcinoma and pluripotent testicular embryonic carcinoma cells. Int. J. Mol. Sci.16 (9):22711-22734(SCI; IF = 4.183; Rank = 26.74% in Biochemistry & Molecular Biology).

12. Lo, Y.L.*, Tu, W.C. (2015) Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells. Chemico-Biological Interactions242:13-23(SCI; IF = 3.41; Rank = 29% in Pharmacology & Pharmacy).

13. Lo, Y.L.*, Liu, Y. (2014) Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.PLoS One9(3): e90180 (SCI; IF = 2.78; Rank = 34.78% in Multidisciplinary Sciences).

14. Lo, Y.L.*,Lin, Y, Lin, H.R. (2014) Evaluation of epirubicin in thermogelling and bioadhesive liquid and solid suppository formulations for rectal administration. Int. J. Mol. Sci. 15 (1):342-360(SCI; IF = 4.183; Rank = 26.74% in Biochemistry & Molecular Biology).

15. Lee, Y.K., Lin, T.H. Chang, C.F.^*, Lo, Y.L.*(2013) Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosispathway via β-catenin/GSK-3β modulation in colorectal carcinoma.PLoS One8 (11): e82478 (SCI; IF = 2.78; Rank = 34.78% in Multidisciplinary Sciences).

16. Lo, Y.L.*, Wang, W.J. (2013) Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro. Chemico-Biological Interactions205 (3):188-197(SCI; IF =3.41; Rank = 29% in Pharmacology & Pharmacy).

17. Lin, HR., Hsu, C.Y., Lo, Y.L.*(2013) Preparation and characterization of dual phase transition oral hydrogel for sustained release of epirubicin.International Journal of Polymeric Materials and Polymeric Biomaterials62(14):763-769(SCI; IF = 2.127; 35.06% in Polymer Science).

18. Lo, Y.L.*, Liu, Y., Tsai, J. C. (2013)Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo. Biomed. Pharmacother. 67 (4):261-267(SCI; IF = 3.457; 26% in Pharmacology & Pharmacy).

19. Lo, Y.L.* (2013) A potential daidzein derivative enhances cytotoxicity of epirubicin on human colon adenocarcinoma Caco-2 cells. Int. J. Mol. Sci. 14 (1):158-176 (SCI; IF = 4.183; Rank = 26.74% in Biochemistry & Molecular Biology).

20. Lo, Y.L.*, Hsu, C.Y., Lin, H.R.*(2013) pH- and thermo-sensitive pluronic/poly(acrylic acid) in situ hydrogels for sustained release of an anticancer drug. J. Drug Target. 21 (1):54-66 (SCI; IF = 3.408; 27% in Pharmacology & Pharmacy).

21. Lo, Y.L.*, Wang, W.J., Ho, C.T. (2012) 7,3′,4′-Trihydroxyisoflavone modulates multidrug resistance transporters and induces apoptosis via production of reactive oxygen species. Toxicology 302 (2-3):221-232 (SCI; IF = 3.265; 27% in Pharmacology & Pharmacy).

22. Lo, Y.L.*, Ho, C.T., Tsai, F.L. (2008) Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin.Eur. J. Pharm. Sci. 35(1-2): 52-67 (SCI; IF = 3.5; 26% in Pharmacology & Pharmacy).

23. Lin, H. R.*, Yu, S. P., Kuo, C.J., Kao, H.J., Lo, Y. L., Lin, Y.J. (2007) Pilocarpine-loaded chitosan-PAA nanosuspension for ophthalmic delivery. J. Biomaterials Science-Polymer Edition 18(2):205-221 (SCI; IF = 1.911;Rank: 41.95% in Polymer Science).

24. Kao, H.J., Lo, Y. L., Vong, W. J., and Lin, H. R.* (2006) Treating allergic conjunctivitis using in situ polyelectrolyte gelling systems.J. Biomaterials Science-Polymer Edition 17(10):1191-1205 (SCI; IF = 1.911;Rank: 41.95% in Polymer Science).

25. Kao, H.J., Lin, H. R., Lo, Y. L.*, and Yu, S. P. (2006) Characterization of pilocarpine-loaded chitosan/carbopol nanoparticles.J. Pharm. Pharmacol. 58(2): 179-186 (SCI; IF = 2.309;Rank: 55.75% in Pharmacology & Pharmacy).

26. Lo, Y. L.*, Tsai, J. C., Kuo, J. H. (2004)Liposomes and disaccharides as carriersin spray-dried powder formulations of superoxide dismutase.J. Control. Release94 (2-3): 259-272 (SCI; IF = 7.901; Rank = 3.3%in Pharmacology & Pharmacy).

27. Tsai, J.C.*, Lo, Y. L., Lin, C.Y., Sheu, H.M., and Lin, J.C. (2004)Feasibility of rapidquantitation of stratum corneum lipid content by Fourier transform infrared spectrometry. Spectroscopy 18: 423-431 (SCI; IF = 0.86;Rank: 77.91% in Spectroscopy).

28. Lo, Y. L.* (2003) Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines.J. Control. Release 90 (1): 37-48(SCI; IF = 7.901; Rank = 3.3% in Pharmacology & Pharmacy).

29. Tsai, J. C.*, Lin, C. Y., Sheu, H. M., and Lo, Y. L. (2003) Noninvasive characterization of regional variation in drug transport across human stratum corneum in vivo.Pharm. Res. 20(4): 632-638(SCI; IF = 3.335;Rank: 28.16% inPharmacology & Pharmacy). 

30. Kuo, J. H., Lo, Y. L., Shau, M. D., Cherng, J. Y.* (2002) A thermodynamic study of cationic polymer-plasmid DNA complexes by high-sensitive differential scanning calorimetry. J. Control. Release 81(3): 321-325 (SCI; IF = 7.901; Rank = 3.3% in Pharmacology & Pharmacy).

31. Tsai, J. C.*, Chen, I. H., Wong, T. K., and Lo, Y. L. (2002)In vitro/in vivo correlations between transdermal delivery of 5-aminolaevulinic acid and cutaneous protoporphyrin IX accumulation and effect of formulation.Br. J. Dermatology 146: 853-862 (SCI; IF = 6.129;Rank: 5.47% in Dermatology).

32. Lo, Y. L.,Liu, F. I., and Cherng, J. Y.*(2001) Effect of PSC 833 liposomes and Intralipid on the transport of epirubicin in Caco-2 cells and rat intestines. J. Control. Release76: 1-10(SCI; IF = 7.901; Rank = 3. 3% in Pharmacology & Pharmacy).

33. Lo, Y. L.* (2000) Phospholipids as multidrug resistance modulators on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem. Pharmacol. 60: 1381-1390 (SCI; IF = 4.235;Rank: 13.60% in Pharmacology & Pharmacy).

34. Lo, Y. L.*,Liu, F. I., Yang, J. M., and Cherng, J. Y. (2001) Reversal of multidrug resistance to epirubicin by cyclosporin A in liposomes or intralipid. Anticancer Res.21(1A): 445-450 (SCI; IF = 1.9;Rank: 82% in Oncology).

35. Lo, Y. L.* and Huang, J. D. (2000) Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem. Pharmacol. 59: 665-672 (SCI; IF = 4.235;Rank: 13.60% in Pharmacology & Pharmacy).

36. Lo, Y. L.* and Huang, J. D. (1999) Comparison of effects of natural or artificial rodent diet on etoposide absorption in rats. In Vivo 13: 51-56 (SCI; IF = 1.116;Rank: 85% in Medicine, Research & Experimental).

37. Lo, Y. L.*(1999)Use of phospholipids to enhance the intestinal absorption of epirubicin. Chia-Nan Annu. Bull.25: 139-146(NSC 88-2314-B-041-009).

38. Lo, Y. L.*, Hsu, C. Y. and Huang, J. D. (1998) Comparison of effects of surfactants with other MDR reversing agents on intracellular uptake of epirubicin in Caco-2 cell line. Anticancer Res. 18: 3005-3009 (SCI; IF = 1.9;Rank: 82% in Oncology).

39. Lo, Y. L.*, Hsu, L. R., Song, C. L., Tsaz, Y. F., Chen, C. M., and Wu, D. H. (1998) Use of Cremophor EL as a MDR reversing agent to enhance intestinal absorption of epirubicin in everted gut sacs of rats and human intestinal epithelial Caco-2 cell layers. Chia-Nan Annu. Bull. 24: 142-149 (NSC 87-2314-B-041-008).

40. Lo, Y. L.* and Rahman, Y. E. (1998) Effect of lipids on the thermal stability and conformational changes of proteins: Ribonuclease A and cytochrome c. Int. J. Pharm. 161(2): 137-148 (SCI; IF = 3.9;Rank: 17%inPharmacology & Pharmacy).

41. Lo, Y. L.*, Hsu, C. Y. and Huang, J. D. (1997) Use of pharmaceutical excipient Cremophor EL for enhancing intracellular accumulation of epirubicin in Caco-2 cell line.Chia-Nan Annu. Bull. 23: 18-24.

42. Lo, Y. L. and Rahman, Y. E.* (1996) Interaction between superoxide dismutase and dipalmitoylphosphotidylglycerol bilayers: a fourier transform infrared (FT-IR) spectroscopic study. Pharm. Res. 13(2): 265-271 (SCI; IF = 3.3;Rank: 28% inPharmacology & Pharmacy).

43. Lo, Y. L.* and Rahman, Y. E. (1995) Protein location in liposomes, a drug carrier: a prediction by differential scanning calorimetry. J. Pharm. Sci. 84(7): 805-814 (SCI; IF = 3.1; Rank: 34.7% in Pharmacology & Pharmacy).

○ 研討會論文（共計發表四十八篇論文於國際研討會及五十四篇論文於國內研討會）

1. Lo, Y.L.*, Chen, Y.C., Chang, C.H., Tseng, W.H., Wang, C.S.(2019) Tumor-targeted and pH-shiftable nanoparticles to encapsulate oxaliplatin and microRNA for colorectal cancer therapy. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, USA.

2. Juang, V., Chen, Y.C.,Lo, Y.L.*(2019) The use of EGFR-TKI-loaded lipid polymeric nanoparticles for suppression of colorectal cancer. 2019 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, San Antonio, Texas, USA.

3. Chang, C.H., Wang, C.S.,Lo, Y.L.*(2019) The use of microRNA- and irinotecan-loaded targeting nanoparticles to improve cancer-specific therapy.2019 Annual Meeting of the Controlled Release Society, Valencia, Spain.

4. Chang, C.H., Wang, C.S.,Lo, Y.L.* (2019)pH-responsive and targeting peptide-modified nanoparticles for dual-delivery of irinotecan and microRNA to inhibit cancer. 2019 International Advanced Drug Delivery Symposium & Annual Meeting of Biomaterials and Controlled Releases Society in Taiwan, Hsinchu, Taiwan.

5. Chang, C.H., Wang, C.S.,Lo, Y.L.*(2019) Multifunctional nanoparticles encapsulating chemotherapy and microRNA for tumor suppression. The 34 Joint Annual Conference of Biomedical Science (第34屆生物醫學聯合學術年會; 投稿學會：台灣藥理學會), Taipei, Taiwan.

6. Lo, Y.L.*, Juang, V., Lee, H.P., Lin, A.M.Y. (2018) PEGylated liposomes for delivering anticancer drugs and antimicrobial peptides: new approaches for cancer nanomedicines. Taiwan-Japan Joint Symposium, Sapporo, Japan.

7. Lin, L.Y., Chen, Y.C., Wang, C.S., Lo, Y.L.* (2018) The effect of microRNA and natural compound E encapsulated in nanoparticles for inhibition of oral cancer cells. Asia Pacific Pharmaceutical Symposium at Fujiyoshida-shi, Yamanashi-ken, Japan.

8. Lo, Y.L.*, Juang, V., Wang, C.S., Lin, G.L., Ting, H.J. (2018) Silencing of human antigen R protein increases the sensitivity of cancer cells to combination therapy.Immuno‐Oncology 2018 World Congress (Immuno‐Oncology 2018),Vienna, Austria.

9. Juang, V., Chen, Y.C.,Lo, Y.L.* (2018) Environment-responsive multifunctional nanoparticles encapsulating chemotherapy and microRNA to suppress cancer cells. 2018 Annual Meeting of the Controlled Release Society, New York City, New York, USA.

10. Chen, Y.C., Juang, V.,Lo, Y.L.*(2018) pH-responsive nanoparticles encapsulating oxaliplatin and microRNA for inhibition of colorectal cancer cells. The 33 Joint Annual Conference of Biomedical Science (第33屆生物醫學聯合學術年會; 投稿學會：台灣藥理學會), Taipei, Taiwan.

11. Wang, C.S., Lo, Y.L.*, Juang, V., Lin, G.L., Ting, H.J. (2018) HuR siRNA reduced resistance to chemotherapy in cancer cells. The 33 Joint Annual Conference of Biomedical Science, Taipei, Taiwan.

12. Lo, Y.L.*, Juang, V., Wang, C.S., Lin, G.L., Ting, H.J. (2018) Apoptosis-mediated cell death via human antigen R silencing in colon cancer cells. A Matter of Life or Death: From Basic Cell Death Mechanisms to Novel Cancer Treatments, Amsterdam, Netherlands.

13. Chen, Y.C., Juang, V.,Lo, Y.L.*(2018) Environment-responsive nanoparticles carrying chemotherapy and microRNA for suppressing cancer. 2018 Conference of the Pharmaceutical Society of Taiwan, Tainan, Taiwan (2018年台灣藥學年會藥劑組口頭論文報告優等).

14. Chen, Y.C., Chang, M.H., Li, F.Y., Chu, C.Y., Yang, C.P., Chang, Y.H., Chen, C.J., Lo, Y.L.* (2018) Hypoglycemic and hypolipidemic effects of multi-component nanoparticles on adipocytes and obese mice. 2018 Conference of the Pharmaceutical Society of Taiwan, Tainan, Taiwan.

15. Wang, C.S., Lin, G.L., Ting, H.J.,Lo, Y.L.* (2018) siRNA targeting human antigen R protein reduced chemotherapy resistance in cancer cells. 2018 Conference of the Pharmaceutical Society of Taiwan, Tainan, Taiwan.

16. Juang, V., Chen, Y.C.,Lo, Y.L.*(2017) Characterization and cytotoxicity of microRNA- and irinotecan-loaded multifunctional nanoparticle complex for inhibiting colorectal cancer cells. 2017 AAPS Annual Meeting, San Diego, CA, USA. Pharm. Res. 00(00): S-000 (SCI).

17. Lo, Y.L.*(2017) Antimicrobial peptides as adjuvants in cationic PEGylated liposomes for delivering antineoplastic agents: a new approach for cancer nanomedicine. 2nd Joint UTAR-UST Symposium on Cancer and Stem Cell Research, Taipei, Taiwan (獲邀演講).

18. Juang, V., Chen, Y.C.,Lo, Y.L.*(2017) Peptide-modified liposomes encapsulating irinotecan for inhibition of colorectal cancer. The 32nd Joint Annual Conference of Biomedical Science (第32屆生物醫學聯合學術年會; 投稿學會：台灣藥理學會), Taipei, Taiwan.

19. Hong, S.T., Lo, Y.L.*, Lin, M.Y. (2017) Afatinib encapsulated in peptides-coated nanoparticles for brain delivery. The 32nd Joint Annual Conference of Biomedical Science (第32屆生物醫學聯合學術年會; 投稿學會：台灣藥理學會), Taipei, Taiwan.

20. Zhao, W.Z., Wang, H.T., Huang, H.J., Lo, Y.L.*, Lin, A.M.Y.* (2017) Neuroprotective effects of baicalein on acrolein-induced neurotoxicity in the nigrostriatal dopaminergic system of rat brain. The 32nd Joint Annual Conference of Biomedical Science (第32屆生物醫學聯合學術年會; 投稿學會：台灣藥理學會), Taipei, Taiwan.

21. Cheng, Y.N., Yang, C.P., Lo, Y.L., Chang, Y.H., Chen, C.J.* (2017) 利用 leptin 145E/145E 小鼠動物模式探討第四型介白素與微小RNA 對脂肪分化及脂質代謝平衡的影響. 2016榮台聯大成果發表會, Taipei, Taiwan.

22. Yang, C.P., Chen, C.J., Lo, Y.L., Chang, Y.H.* (2017) 利用 leptin 145E/145E 小鼠動物模式探討第四型介白素與微小RNA 對脂肪分化及脂質代謝平衡的影響. 2016榮台聯大成果發表會, Taipei, Taiwan.

23. Li, F.Y., Chu, C.Y., Chen, Y.C., Yang, C.P., Chang, Y.H., Chen, C.J., Lo, Y.L.*(2017) 藥物及天然物奈米粒對leptin 145E/145E 小鼠動物模式的效應探討. 2016榮台聯大成果發表會, Taipei, Taiwan.

24. Juang, V.,Lee, H.P., Lin, A.M.Y.,Lo, Y.L.*(2016) Antimicrobial peptide-modified cationic PEGylated liposomes for delivering anticancer drugs to overcome multidrug resistance. 2016 Conference of the Pharmaceutical Society of Taiwan, Taipei, Taiwan (獲選為2016年台灣藥學年會藥劑組口頭論文報告).

25. Lin, K.H., Hong, S.T., Lo, Y.L.*, Lin, M.Y.,Yang, J.C.H. (2016) Enhancing gefitinib delivery across the blood-brain barrier using liposomes modified with peptides. 2016 Conference of the Pharmaceutical Society of Taiwan, Taipei, Taiwan (榮獲2016年台灣藥學年會暨學術研討會壁報比賽藥劑組第一名).

26. Li, F.Y., Chu, C.Y., Chen, Y.C., Yang, C.P., Chang, Y.H.,Lo, Y.L.*(2016) Effects of natural compound-loaded nanoparticles on metabolism of carbohydrates and lipids. 15th Meeting of Consortium for Globalization of Chinese Medicine (CGCM), Taipei, Taiwan.

27. Zhao, W.Z., Wang, H.T., Huang, H.J., Lo, Y.L.*, Lin, A.M.Y.*(2016) Neuroprotective effects of baicalein on acrolein-induced neurotoxicity in the nigrostriatal dopaminergic system of rat brain. 13th International Conference on Neuroprotective Agents (ICNA), Bilbao, Spain.

28. Lo, Y.L.*, Tu, W.C., Lee, H.P. (2016) A nanoformulation of antimicrobial peptides and anticancer drugs in PEGylated liposomes inhibits multidrug resistance in different cancer cells. 2016 International Symposium on Theranostic Nanomedicine, Hsinchu, Taiwan.

29. Lin K.H., Lin, M.Y., Yang, J.C.H., Lo, Y.L.*(2016) Enhancing EGFR-TKIdeliveryacross the blood-brain barrier usingpharmaceutical excipients. The 31^st Joint Annual Conference of Biomedical Science (第三十一屆生物醫學聯合學術年會; 投稿學會：台灣藥理學會), Taipei, Taiwan.

30. Lo, Y.L.*, Liu, Y.H., Ting, H.J. (2016) The use of zebrafish as a screening platform of anticancer agents. The 31^st Joint Annual Conference of Biomedical Science (第三十一屆生物醫學聯合學術年會; 投稿學會：台灣藥理學會), Taipei, Taiwan.

31. Chen, L.Y.J., Ho, W.C., Lo, Y.L., Yang, J.C.H., Lin, M.Y.*(2016) Role of EGFR in the astrocytes in response to hypoxia: potential neuroprotection of EGFR-TKIs. The 31^st Joint Annual Conference of Biomedical Science (第三十一屆生物醫學聯合學術年會; 投稿學會：台灣藥理學會), Taipei, Taiwan.

32. Juang V.,Lee, H.P., Lo, Y.L.*(2016) Anticancer mechanisms of liposomal epirubicin and antimicrobial peptide TH2-3 on cervical cancer cells. The 31^st Joint Annual Conference of Biomedical Science (第三十一屆生物醫學聯合學術年會; 投稿學會：台灣藥理學會), Taipei, Taiwan.

33. Lo, Y.L.*, Liu, Y.H., Ting, H.J.,Tseng, D.Y. (2015) Development of a novel screening platform of anticancer agents using zebrafish as a model. 2015 Taiwan Zebrafish Symposium, Taipei, Taiwan.

34. Lo, Y.L.*, Tu, W.C., Lee, H.P.(2015) The development of antimicrobial peptides as adjuvants to the current chemotherapy. The 7^thAsian Association of Schools of Pharmacy (AASP) Conference (2015亞洲藥學院校聯合會大會), Taipei, Taiwan.

35. Lo, Y.L.*,Liu, Y.H., Ting, H.J. (2015) The use of an antimicrobial peptide from Red Sea sole as a multidrug resistance modulator in human cervical cancer cells. 14th Meeting of Consortium for Globalization of Chinese Medicine (CGCM), London ON, Canada.

36. Lo, Y.L.*,Tu, W.C. (2015) Development of CHY-1, an antimicrobial peptide and epirubicin in liposomes as an effective nanomedicine. The 30^th Joint Annual Conference of Biomedical Science (第三十屆生物醫學聯合學術年會; 投稿學會：台灣藥理學會), Taipei, Taiwan.

37. Lin, G.L., Ting, H.J.,Lo, Y.L.* (2015) The role of HuR in mediating the effect of epinecidin-1 and/or epirubicin in colon adenocarcinoma SW620 cells.The 30^th Joint Annual Conference of Biomedical Science (第三十屆生物醫學聯合學術年會; 投稿學會：台灣生理學會), Taipei, Taiwan.

38. Wang*, Y.T., Wang,H.T.Huang, H.J., Lo, Y.L., Lin, M.Y. (2015) Oral acrolein induces neurotoxicity in rat brain: the involvement of apoptosis and neuroinflammation.The 30^th Joint Annual Conference of Biomedical Science (第三十屆生物醫學聯合學術年會; 投稿學會：台灣藥理學會), Taipei, Taiwan.

39. Liu, Y.H., Ting, H.J.,Lo, Y.L.* (2015) Development of Antimicrobial Peptides as Adjuvants of Epirubicin, Conference of Bioresources and Technology, Tainan, Taiwan.

40. Lin, G.L., Ting, H.J.,Lo, Y.L.* (2015) The role of HuR in mediating the effect of antimicrobial peptide and/or anticancer drug in colon adenocarcinoma cells. Conference of Bioresources and Technology, Tainan, Taiwan (榮獲壁報比賽第一名).

41. Lo, Y.L.*, Lee, H.P. (2014) Hepcidin incorporated in liposomes as a new adjuvant to epirubicin. 7^th World Congress on Preventive and Regenerative Medicine (第七屆預防與再生醫學世界年會), Taipei, Taiwan.

42. Lo, Y.L.*,Tu, W.C.(2014)The anticancer mechanisms of an antimicrobial peptide and epirubicin on human cervical cancer cells. The 7th Asian Pacific Organization forCell Biology Congress, Biopolis, Singapore.

43. Lo, Y.L.*, Lee, H.P. (2014)Development of an antimicrobial peptide from tilapia as a new adjuvant to the current antineoplastic agent. The 29^th Joint Annual Conference of Biomedical Science (第二十九屆生物醫學聯合學術年會; 投稿學會：台灣藥理學會), Taipei, Taiwan.

44. Lo, Y.L.*,Lin, Y.J.,Lin, H.R.(2013)Colonic delivery of an antineoplastic agent in thermogelling and bioadhesive suppository formulations.The 13th Pacific Polymer Conference, Kaohsiung, Taiwan.

45. Lo, Y.L.*, Wang, W.J. (2012)The study of anticancer mechanisms of daidzein in combination with epirubicin on human cervical cancer HeLa cells. The 39th Annual Meeting of the Controlled Release Society, Québec City, Canada.

46. Lo, Y.L.*, Hsu,C.Y.,Lin, H.R.(2011)抗癌藥物之原位成膠輸送系統, 100年度「生化及藥理醫學學門」新知暨學術交流研討會, Taichung, Taiwan.

47. Lo, Y.L.*, Ho, C.T., Liu, Y.(2010)The cytotoxic effect and mechanisms of antisense oligonucleotides and epirubicin in liposomes on cancer cells. Conference of the Pharmaceutical Society of Taiwan, Taipei, Taiwan.

48. C. Y., Hsu, Lo, Y.L.* (2010)口服原位成膠抗癌藥物輸送系統, 2010南台灣綠色能源、生技醫療產業技術發表會, Kaohsiung, Taiwan.

49. Lo, Y.L.*, Ho, C.T., Liu, Y.(2010)A novel delivery system of antisense oligonucleotides and epirubicin for modulation of multidrug resistance. The 37^thAnnual Meeting of the Controlled Release Society, Portland, Oregon, USA.

50. Lo, Y.L.*, Lin M.F., Ho, C.T. (2009)Useof anethole and epirubicin to inhibit pump and non-pump multidrug resistance. The 36^thAnnual Meeting of the Controlled Release Society, Copenhagen, Denmark.

51. Lo, Y.L.*, Ho, C.C., Ho, C.T. (2008)The effects and mechanisms of hesperidin and hesperetin on inhibiting pump and non-pump multidrug resistance. The IX^th World Congress on Clinical Pharmacology and Therapeutics, Quebec, Canada.

52. Lo, Y.L.*, Ran, R.L., Ho, C.T. (2008)Effects and mechanisms of luteolin on modulation of multidrug resistance and induction of apoptosis in Caco-2 cells.The 35^thAnnual Meeting of the Controlled Release Society, New York, NY, USA.

53. Tsai, C.S. and Lo, Y.L.* (2007)Effect of natural antioxidant on induction of apoptosis.2007 Annual Meeting of the Pharmaceutical Society of Taiwan, Tainan, Taiwan.

54. Ho, C.C. and Lo, Y.L.* (2007) Effect of Hesperitin on apoptosis induction in Caco-2 cells.The 1^st International Cancer Symposium in CMU&H, Taichung, Taiwan.

55. Lin, M.F. and Lo, Y.L.* (2007) Effect of Emodin on apoptosis induction in Caco-2 cells.The 1^st International Cancer Symposium in CMU&H, Taichung, Taiwan.

56. Ran, R.L. and Lo, Y.L.* (2007) Effect of Combination of Apigenin with Epirubicin on the Induction of Apoptosis in Caco-2 Cells. The 1^st International Cancer Symposium in CMU&H, Taichung, Taiwan.

57. Lo, Y.L.*, Ho, C.T., Tsai, F.L. (2007)Effects and mechanisms of glycocholic acid on modulation of multidrug resistance and induction of apoptosis in Caco-2 cells. The 34^thAnnual Meeting of theControlled Release Society, Long Beach, CA, USA.

58. Ho, C.C. and Lo, Y.L.* (2007) Effect of Naringenin on apoptosis induction in Caco-2 cells. 22nd Symposium on Natural Products, Kaohsiung, Taiwan.

59. Ran, R.L. and Lo, Y.L.* (2007) Effect of Combination of Luteolin with Epirubicin on the Induction of Apoptosis in Caco-2 Cells. 22nd Symposium on Natural Products, Kaohsiung, Taiwan.

60. Lin, M.F. and Lo, Y.L.* (2007) Effect of silymarin on apoptosis induction in Caco-2 cells. The 22th Joint Annual Conference of Biomedical Sciences, Taipei, Taiwan.

61. Ho, C.H. and Lo, Y.L.* (2006)Effect and mechanisms of biochanin A on apoptosis induction in Caco-2 cells. Conference of the Pharmaceutical Society of Taiwan, Taichung, Taiwan.

62. Ziu, R.L. and Lo, Y.L.* (2006)Enhancement in apoptosis induction by the combination of estrogen and epirubicinin Caco-2 cells. Conference of the Pharmaceutical Society of Taiwan, Taichung, Taiwan.

63. Lo, Y.L.*, Ho, C.T., Wu, Y.C. (2006)Effects and mechanisms of multiple modulators of p-glycoprotein and multidrug resistance-associated proteins on intestinal transport of epirubicin. The 33^rdAnnual Meeting of the Controlled Release Society, Vienna, Austria.

64. Lin, H.R., Kao, H.J., Lo, Y.L.*, andVong, W.J. (2006) In-situ polyelectrolyte gelling systems for treating allergic conjunctivitis.The 33^thAnnual Meeting of the Controlled Release Society, Vienna, Austria.

65. Lo, Y.L.*, Tsai, F.L., and Chen, C.R. (2005)Effect of glycocholic acid as a multidrug resistance modulator on the induction of apoptosis in Caco-2 cells. Conference of the Pharmaceutical Society of Republic of China, Tainan, Taiwan.

66. Kao, H.J., Lo, Y.L.*, Vong, W.J., and Lin H.R. (2005)In situ gelling polymers as ophthalmic delivery systems of cromolyn. Conference of the Pharmaceutical Society of Republic of China, Tainan, Taiwan.

67. Lin, H. R., Yu, S.Y., Kuo, C. J., Kao, H. J., and Lo, Y.L. (2005) Chitosan-PAA nanoparticles for ophthalmic delivery of pilocarpine, 32^nd Annual Meeting of the Controlled Release Society, Miami Beach, Florida.

68. Lo, Y.L.* andTsai, J.C. (2005)Stabilization of spray-dried superoxide dismutase by liposomes and disaccharides: thermodynamic, conformational, and activity studies. Conference of the Chinese Society of Cell and Molecular Biology, Kenting, Taiwan.

69. Yu, S.Y., Lin, H. R., Kuo, C. J., Kao, H. J., and Lo, Y.L. (2005) Chitosan-PAA nanoparticles for ophthalmic drug delivery, Taiwan Chitin-Chitosan Symposium, Tainan, Taiwan.

70. Tsai, F.L. andLo, Y.L.*(2005)Effects of ursodeoxycholic acid and deoxycholic acid on the modulation of multidrug resistance-relatedproteins, P-glycoprotein, MRP1, MRP2, MRP3, and MRP4. Conference of the Chinese Society of Cell and Molecular Biology, Kenting, Taiwan.

71. Kao, H.J., Lo, Y.L., Lin H.R., and S. P. Yu (2004) In vitro/ in vivo study of pilocarpine-loaded chitosan/carbopol nanoparticles. Conference of the Pharmaceutical Society of Republic of China, Taipei, Taiwan.

72. Tsai, F.L. andLo, Y.L.*(2004)Effects of glycocholic acid as a multidrug resistance modulator on the intestinal uptake of epirubicin. Conference of the Pharmaceutical Society of Republic of China, Taipei, Taiwan.

73. Yu, S.Y., Lin, H. R., Kuo, C. J., Kao, H. J., and Lo, Y.L. (2004) Chitosan-PAA nanoparticles for ophthalmic drug delivery of pilocarpine, 2004 International Symposium on Nano Science and Technology, Tainan, Taiwan.

74. Lo, Y.L.*and Wu, Y.J. (2004) Modulation of multidrug resistance by natural compounds in Caco-2 cells. 8^th World Congress on Clinical Pharmacology and Therapeutics, Brisbane, Australia.

75. Yu, S.Y., Lin, H. R., Kuo, C. J., Kao, H. J., and Lo, Y.L. (2004) Chitosan-PAA nanoparticles for ophthalmic delivery of pilocarpine, Taiwan-Japan Advanced Biomaterials Symposium, Taipei, Taiwan.

76. Lo, Y.L.* (2004) Stabilization of spray-dried superoxide dismutase by liposomes and chitosan: surface characterization and relationship between activity and formulations. ROC-Japan Joint Symposium onParticle Design, Nanotechnology, and Drug Delivery, Hsinchu, Taiwan, R.O.C.

77. Lo, Y.L.*, Dong, R.N., and Guo, H.C. (2004) Thermodynamic, conformation, and activity studies of protein-loaded liposomes with surfactants.ThePharmaceutical Symposium, Pingtung, Taiwan, R.O.C.

78. Gao, H.J. and Lo, Y.L.*(2003) Study of pilocarpine-loaded chitosan/poly (acrylic acid) nanoparticles.Conference of the Pharmaceutical Society of Republic of China, Taipei, Taiwan, R.O.C.

79. Lo, Y.L.*(2003) Aerosol powder performance, interaction, and stability of spray-dried protein-loaded liposomes. Conference of the Pharmaceutical Society of Republic of China, Taipei, Taiwan, R.O.C.

80. Lo, Y.L.*and Gao, H.J. (2003) A Novel design of spray-dried protein-loaded liposomes. Conference of the Pharmaceutical Society of Republic of China, Taipei, Taiwan, R.O.C.

81. Wu, Y.J.and Lo, Y.L.* (2003) Effect of natural compounds as multidrug resistance modulators on the intestinal transport of epirubicin. Conference of the Pharmaceutical Society of Republic of China, Taipei, Taiwan, R.O.C.

82. Lo, Y.L.*, Kuo, J. H.(2002) Surface characterization of spray-dried superoxide dismutaseformulations.Conference of the Pharmaceutical Society of Republic of China, Pingtung, Taiwan, R.O.C.

83. Kuo, J.H.,Lo, Y.L.*,Cherng, J.Y., Shau, M.D.(2001) The stabilization study of biopolymers by spray-drying. The Joint Annual Conference of Polymer, Taipei, Taiwan, R.O.C.

84. Lo, Y.L.*,Kuo, J.H., Cherng, J.Y., Shau, M.D. (2001)Surface characterization and activity of lyophilized superoxide dismutase-loaded liposomes with different cryoprotectants. Conference of the Pharmaceutical Society of Republic of China, Taipei, Taiwan, R.O.C.

85. Tsai, J.C.*, Chen, I.H., Wong, T.K., and Lo, Y.L. (2001)In vitro/in vivo correlation between transdermal delivery of 5-aminolevulinic acid and cutaneous PpIX accumulation and effect of formulation. Conference of the Pharmaceutical Society of Republic of China, Taipei, Taiwan, R.O.C.

86. Tsai, J.C.*, Lin, C.Y., Sheu, H.M., and Lo, Y.L.(2001)Rapid Infrared Spectrometric Quantitation of Stratum Corneum Lipid Content. Stratum Corneum III Conference, Basel, Switzerland

87. Cherng, J.Y., Kuo, J.H.*, Lo, Y.L., Shau, M.D. (2001) Pharmaceutical aspects of polymer-based gene delivery systems.The 28^th International Symposium on Controlled Release of Bioactive Materials, San Diego, CA, USA.

88. Lo, Y.L.*,Chen, L.T.,Lai, Y.W., and Chuang, Y.C. (2001)Effects of adjuvants on the stability of superoxide dismutase-loaded liposomes during freeze-drying, storage in the dried solid and incubation in the blood components. The 28^th International Symposium on Controlled Release of Bioactive Materials, San Diego, CA, USA.

89. Cherng, J.Y.*, Kuo, J.H., Lo, Y.L., Shau, M.D. (2001) 非病毒性載體（高分子聚合物）應用於基因傳輸系統之研究. The 2001 Global Chinese Symposium on Biomaterials and Controlled Release, Taipei, Taiwan, R.O.C.

90. Tsai, J.C.*, Lin, C.Y., Sheu, H.M., and Lo, Y.L.(2000) Regional variation in stratum corneum permeability of 4-cyanophenol vs cimetidine by ATR-FTIR spectroscopy.2000 AAPS Annual Meeting, Indianapolis, IN, USA.

91. Lo, Y.L.* and Chang, C.Y. (2000)Effect of cryoprotectants on the stability of superoxide dismutase liposomes. Conference of the Pharmaceutical Society of Republic of China, Taipei, Taiwan, R.O.C.

92. Lo, Y.L.* and Chen, C.R. (2000)Effect of superdisintegrants on the transport of epirubicin in Caco-2 cells and rat intestines. Conference of the Pharmaceutical Society of Republic of China, Taipei, Taiwan, R.O.C.

93. Lo, Y.L.*(2000) Effects of pharmaceutical excipients on the drug transport by P-glycoprotein. The Pharmaceutical symposium on Y2K, Pingtung, Taiwan, R.O.C.

94. Tsai, J.C.*, Lin, C.Y., Sheu, H.M., and Lo, Y.L.(2000) Characterization of regional variation in human stratum corneum permeability by ATR-FTIR spectroscopy.The Pharmaceutical symposium on Y2K, Pingtung, Taiwan, R.O.C.

95. Lo, Y.L.*,Chang, C.J., and Liu, F.I. (1999)Reversal of multidrug resistance of epirubicin by two different dosage forms of cyclosporines. Conference of the Pharmaceutical Society of Republic of China, Kaohsiung, Taiwan, R.O.C.

96. Lo, Y.L.* (1999) Liposomal encapsulation on the efflux of epirubicin by P-glycoprotein. The 1999 Global Chinese Symposium on Biomaterials and Controlled Release, Taipei, Taiwan, R.O.C.

97. Hsu, C.Y., Lo, Y.L., and Huang, J.D.* (1998) The effects of bovine serum albumin (BSA) on the epirubicin transport by P-glycoprotein. The Thirteen Joint Annual Conference of Biomedical Sciences, Taipei, Taiwan, R.O.C. 

98. Lo, Y.L.* and Rahman, Y.E. (1995) Effects of membrane binding on the thermal stability of proteins using differential scanning calorimetry (DSC). AAPS Midwest Regional Meeting, Chicago, IL, USA.

99. Lo, Y.L. and Rahman, Y.E.* (1995) Effects of Membrane binding on the conformational changes of proteins using Fourier transform infrared (FT-IR) spectroscopy. American Chemical Society 210th National Meeting, Chicago, IL, USA (SCI).

100. Lo, Y.L.* and Rahman, Y.E. (1995) Effects of Membrane binding on the thermal stability and conformational changes of proteins using differential scanning calorimetry (DSC) and Fourier transform infrared (FT-IR) spectroscopy. AAPS Tenth Annual Meeting, Miami Beach, FL, USA. Pharm. Res. 12(9): S-209 (SCI).

101. Lo, Y.L. and Rahman, Y.E.* (1995) Conformational changes of superoxide dismutase in DPPG liposomes using Fourier transform infrared (FT-IR) spectroscopy. AAPS Tenth Annual Meeting, Miami Beach, FL, USA. Pharm. Res. 12(9): S-209 (SCI).

102. Lo, Y.L. and Rahman, Y.E.* (1994) Prediction of protein drug location in liposomes by differential scanning calorimetry (DSC). AAPS Ninth Annual Meeting, San Diego, CA, USA. Pharm. Res. 11(10): S-324 (SCI).